BELANO Medical - The Micro­biotics Company


Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study.

Reducing the amount of Helico­bacter pylori in the stomach by selective bacterial–bacterial cell inter­action was sought as an effective and novel method for combating the stomach pathogen. Lacto­ba­c­illus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lacto­ba­c­illus species. C. Holz, A. Busjahn, H. Mehling, S. Arya, M. Boettner, H. Habibi, C. Lang (2014) Probiotics & Antimicro. Prot. 7: 91-100 
Scroll to Top